NEJM publishes full analysis of Rydapt® (midostaurin) phase III RATIFY trial
Novartis announced that full results from the Rydapt [®] (midostaurin) Phase III RATIFY (CALGB 10603 [Alliance]) clinical trial were published in The New England Journal of Medicine. New data include DFS, further analysis of patients undergoing transplant and expanded safety information. June 23, 2017